CL2012002540A1 - Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras. - Google Patents

Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.

Info

Publication number
CL2012002540A1
CL2012002540A1 CL2012002540A CL2012002540A CL2012002540A1 CL 2012002540 A1 CL2012002540 A1 CL 2012002540A1 CL 2012002540 A CL2012002540 A CL 2012002540A CL 2012002540 A CL2012002540 A CL 2012002540A CL 2012002540 A1 CL2012002540 A1 CL 2012002540A1
Authority
CL
Chile
Prior art keywords
anxiety
stress
treatment
pharmaceutical composition
preparation
Prior art date
Application number
CL2012002540A
Other languages
English (en)
Inventor
Hanbin Shan
Zhedong Yuan
Xueyan Zhu
Peng Zhang
Hongjuan Pan
Xiong Yu
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44599556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002540(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CL2012002540A1 publication Critical patent/CL2012002540A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups

Abstract

Compuesto cristalino hidrato del hidrocloruro de agomelatina; método de preparación del compuesto; composición farmacéutica; uso del compuesto para el tratamiento de trastornos del sueño, estrés, ansiedad, depresión mayor, enfermedades cardiovasculares, entre otras.
CL2012002540A 2010-03-17 2012-09-13 Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras. CL2012002540A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201010126254XA CN102190594A (zh) 2010-03-17 2010-03-17 阿戈美拉汀氯化氢水合物及其制备方法

Publications (1)

Publication Number Publication Date
CL2012002540A1 true CL2012002540A1 (es) 2013-01-11

Family

ID=44599556

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002540A CL2012002540A1 (es) 2010-03-17 2012-09-13 Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.

Country Status (36)

Country Link
US (1) US8729131B2 (es)
EP (1) EP2547649B1 (es)
JP (1) JP5634532B2 (es)
KR (1) KR101406727B1 (es)
CN (2) CN102190594A (es)
AP (1) AP2012006492A0 (es)
AU (1) AU2011229618B2 (es)
BR (1) BR112012023317B1 (es)
CA (1) CA2792417C (es)
CL (1) CL2012002540A1 (es)
CR (1) CR20120462A (es)
CU (1) CU20120137A7 (es)
CY (1) CY1116086T1 (es)
DK (1) DK2547649T3 (es)
EA (1) EA022067B1 (es)
EC (1) ECSP12012155A (es)
ES (1) ES2530772T3 (es)
GE (1) GEP20156231B (es)
GT (1) GT201200259A (es)
HK (1) HK1177451A1 (es)
HR (1) HRP20150071T1 (es)
IL (1) IL221782A (es)
MA (1) MA34055B1 (es)
ME (1) ME02054B (es)
MX (1) MX2012010541A (es)
NI (1) NI201200140A (es)
NZ (1) NZ602450A (es)
PE (1) PE20130013A1 (es)
PL (1) PL2547649T3 (es)
PT (1) PT2547649E (es)
RS (1) RS53815B1 (es)
SG (1) SG183868A1 (es)
SI (1) SI2547649T1 (es)
TN (1) TN2012000435A1 (es)
UA (1) UA105425C2 (es)
WO (1) WO2011113362A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2551257A1 (en) * 2011-07-28 2013-01-30 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of agomelatine with co-crystal-formers
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
WO2013170738A1 (zh) * 2012-05-14 2013-11-21 上海右手医药科技开发有限公司 阿戈美拉汀酸根复合物及其制备方法和用途
CN102702041B (zh) * 2012-05-14 2013-08-14 上海右手医药科技开发有限公司 阿戈美拉汀苯磺酸类复合物及其制备方法
CN102718675B (zh) * 2012-06-07 2015-03-25 上海右手医药科技开发有限公司 阿戈美拉汀甲磺酸复合物及其制备方法
CN102718676B (zh) * 2012-06-26 2014-04-09 福建广生堂药业股份有限公司 阿戈美拉汀硫酸盐及其制备方法
EP2934502A1 (en) 2012-12-21 2015-10-28 Laboratorios Lesvi S.L. Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof
FR3001894A1 (fr) 2013-02-08 2014-08-15 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
WO2015013865A1 (en) * 2013-07-29 2015-02-05 Les Laboratoires Servier Agomelatine sulfonic acids complexes and preparation thereof
KR101470794B1 (ko) * 2014-06-30 2014-12-08 순천향대학교 산학협력단 아고멜라틴 공결정의 제조 방법 및 이를 포함하는 조성물
MA50817B1 (fr) 2015-07-02 2021-10-29 Acerta Pharma Bv Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
US10367757B2 (en) * 2016-08-27 2019-07-30 Nicira, Inc. Extension of network control system into public cloud

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
PL366150A1 (en) * 2000-10-30 2005-01-24 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
FR2890562B1 (fr) * 2005-09-09 2012-10-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
FR2934859B1 (fr) * 2008-08-05 2010-08-13 Servier Lab Nouveau procede de synthese de l'agomelatine
CN101481321B (zh) * 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
WO2012046253A2 (en) * 2010-10-08 2012-04-12 Msn Laboratories Limited Process for the preparation of n-[2- (7-methoxy-l-naphthyl) ethyl] acetamide and its novel crystalline forms

Also Published As

Publication number Publication date
KR20120128712A (ko) 2012-11-27
PL2547649T3 (pl) 2015-04-30
SG183868A1 (en) 2012-10-30
BR112012023317B1 (pt) 2021-07-06
AP2012006492A0 (en) 2012-10-31
BR112012023317A2 (pt) 2016-05-24
PE20130013A1 (es) 2013-01-26
MX2012010541A (es) 2012-10-05
CY1116086T1 (el) 2017-02-08
SI2547649T1 (sl) 2015-03-31
ME02054B (me) 2015-05-20
NZ602450A (en) 2014-12-24
CN102190594A (zh) 2011-09-21
NI201200140A (es) 2012-11-09
EP2547649A1 (en) 2013-01-23
CN102958911B (zh) 2015-11-25
KR101406727B1 (ko) 2014-06-13
RS53815B1 (en) 2015-06-30
CA2792417A1 (en) 2011-09-22
EP2547649A4 (en) 2013-09-04
GT201200259A (es) 2013-12-03
UA105425C2 (ru) 2014-05-12
EA022067B1 (ru) 2015-10-30
ECSP12012155A (es) 2012-12-28
JP2013522241A (ja) 2013-06-13
EP2547649B1 (en) 2014-11-19
CA2792417C (en) 2015-11-24
CU20120137A7 (es) 2012-11-15
CR20120462A (es) 2012-10-05
US20130005820A1 (en) 2013-01-03
ES2530772T3 (es) 2015-03-05
IL221782A (en) 2017-11-30
EA201201294A1 (ru) 2013-04-30
CN102958911A (zh) 2013-03-06
DK2547649T3 (en) 2015-03-02
JP5634532B2 (ja) 2014-12-03
US8729131B2 (en) 2014-05-20
MA34055B1 (fr) 2013-03-05
AU2011229618B2 (en) 2014-05-22
HRP20150071T1 (en) 2015-02-27
AU2011229618A1 (en) 2012-09-27
TN2012000435A1 (en) 2014-01-30
HK1177451A1 (zh) 2013-08-23
WO2011113362A1 (en) 2011-09-22
PT2547649E (pt) 2014-12-29
GEP20156231B (en) 2015-01-26

Similar Documents

Publication Publication Date Title
CL2012002540A1 (es) Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
UY32427A (es) Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
ECSP12012125A (es) Ariltriazolonas ligadas a bisarilo y su uso
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
CL2011002231A1 (es) Forma cristalina vi de la agomelatina; proceso de preparacion; composicion farmaceutica; y su uso para tratar estres, ansiedad, trastornos del sueño, enfermedades cardiovasculares, esquizofrenia, fobia, depresion, enfermedades del sistema digestivo.
CR11818A (es) Derivados de triazol utiles para el tratamiento de enfermedades
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
BR112013009486A2 (pt) processo para preparação de formas de dosagem gastrirretentivas multiparticuladas
CL2013003333A1 (es) Compuestos derivados de pregnenolona, antagonistas de receptor cb1; composicion farmaceutica: y su uso para el tratamiento de trastornos de la vejiga y gastrointestinales, enfermedades inflamatorias, cardiovasculares, entre otras.
AR061311A1 (es) Procesos para preparar clorhidrato de cinacalcet y formas polimorficas del mismo
AR086586A1 (es) Forma cristalina de ciclosporina a, metodos de preparacion y metodos para utilizar la misma
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
CO6660435A2 (es) Una forma cristalina de clorhidrato de (r) -7- cloro-n- (quinuclidin -3-il)benzo[b] tiofeno-2- carboxamida monohodratado
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato